131 related articles for article (PubMed ID: 26995885)
41. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
42. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
43. Serum AMH levels and insulin resistance in women with PCOS.
Sahmay S; Aydogan Mathyk B; Sofiyeva N; Atakul N; Azemi A; Erel T
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():159-164. PubMed ID: 29605710
[TBL] [Abstract][Full Text] [Related]
44. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
45. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
46. [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases].
Hu WH; Qiao J; Li MZ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):721-4. PubMed ID: 17565837
[TBL] [Abstract][Full Text] [Related]
47. Frequency of nodular goiter and autoimmune thyroid disease and association of these disorders with insulin resistance in polycystic ovary syndrome.
Karaköse M; Hepsen S; Çakal E; Saykı Arslan M; Tutal E; Akın Ş; Ünsal İ; Özbek M
J Turk Ger Gynecol Assoc; 2017 Jun; 18(2):85-89. PubMed ID: 28400351
[TBL] [Abstract][Full Text] [Related]
48. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome.
Sharquie KE; Al-Bayatti AA; Al-Ajeel AI; Al-Bahar AJ; Al-Nuaimy AA
Saudi Med J; 2007 Jul; 28(7):1039-43. PubMed ID: 17603706
[TBL] [Abstract][Full Text] [Related]
49. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
Li L; Chen X; He Z; Zhao X; Huang L; Yang D
J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
[TBL] [Abstract][Full Text] [Related]
50. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome.
Yildizhan R; Kurdoglu M; Adali E; Kolusari A; Yildizhan B; Sahin HG; Kamaci M
Arch Gynecol Obstet; 2009 Oct; 280(4):559-63. PubMed ID: 19214546
[TBL] [Abstract][Full Text] [Related]
51. Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome.
Sahin SB; Ayaz T; Cure MC; Sezgin H; Ural UM; Balik G; Sahin FK
Scand J Clin Lab Invest; 2014 Sep; 74(6):465-9. PubMed ID: 24724557
[TBL] [Abstract][Full Text] [Related]
52. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
53. Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow.
Abd El Aal DE; Mohamed SA; Amine AF; Meki AR
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):219-24. PubMed ID: 15653207
[TBL] [Abstract][Full Text] [Related]
54. [Study on the correlation between different Chinese medicine syndrome types and endocrine metabolism of polycystic ovarian syndrome].
Wang XJ; Zeng XL; Liu Y
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Aug; 31(8):1085-9. PubMed ID: 21910340
[TBL] [Abstract][Full Text] [Related]
55. Preptin in women with polycystic ovary syndrome.
Mierzwicka A; Kuliczkowska-Plaksej J; Kolačkov K; Bolanowski M
Gynecol Endocrinol; 2018 Jun; 34(6):470-475. PubMed ID: 29374985
[TBL] [Abstract][Full Text] [Related]
56. [Can hormonal contraceptives affect plasma levels of IGF-1 and IGFBP-1 in slim women with polycystic ovary syndrome?].
Sindelka G; Cibula D; Fanta M; Kasalová Z; Justová V; Lacinová Z; Skrha J
Cas Lek Cesk; 2001 Aug; 140(15):469-72. PubMed ID: 11569168
[TBL] [Abstract][Full Text] [Related]
57. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
58. Serum irisin levels in patients with polycystic ovary syndrome.
Bostancı MS; Akdemir N; Cinemre B; Cevrioglu AS; Özden S; Ünal O
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4462-8. PubMed ID: 26698239
[TBL] [Abstract][Full Text] [Related]
59. Phoenixin-14 concentrations are increased in association with luteinizing hormone and nesfatin-1 concentrations in women with polycystic ovary syndrome.
Ullah K; Ur Rahman T; Wu DD; Lin XH; Liu Y; Guo XY; Leung PCK; Zhang RJ; Huang HF; Sheng JZ
Clin Chim Acta; 2017 Aug; 471():243-247. PubMed ID: 28624500
[TBL] [Abstract][Full Text] [Related]
60. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
Münzker J; Hofer D; Trummer C; Ulbing M; Harger A; Pieber T; Owen L; Keevil B; Brabant G; Lerchbaum E; Obermayer-Pietsch B
J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
